- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04664270
Developing and Implementing E-psychotherapy Program for Mental Health Challenges in Oncology and Palliative Care
Developing and Implementing an Online Psychotherapy Program to Address Mental Health Challenges in Oncology and Palliative Care
The demand for mental health problems, particularly depression and anxiety, is three times greater in Oncology and Palliative Care Centres than in the general population. There are unique factors in this population that make them more susceptible to mental health challenges. The disease itself, the adjustment to a chronic/fatal diagnosis, and the treatment options can all perpetuate the development of mental illness. Despite the well-established association, there have been barriers to access suitable treatment for these patients.
Online Psychotherapy is an effective treatment option that may address many of these barriers. This modality has been proven effective in addressing depression and anxiety in other populations. To date, there has been no psychotherapy module developed specifically for oncology and palliative care patients to our knowledge. The aim is to establish the first academic e-psychotherapy treatment option to address mood and anxiety disorders in oncology and palliative care patients. The investigators will use the Online Psychotherapy Tool (OPTT), a secure cloud-based platform for online delivery of e-CBT, developed by the PI.
The proposed study aims to establish the feasibility and effectiveness of delivering online psychotherapy to oncology and palliative care patients who have a comorbid depressive or anxiety disorder. The patients will be enrolled in an 8-week program with a combination of cognitive behavioural therapy (CBT) and Mindfulness techniques delivered via a series of modules. They will receive individualized feedback from a trained therapist weekly. It is hypothesized that delivering this psychotherapeutic intervention in this manner will have great adherence. The aim is to prove that it will improve the quality of life and decrease symptoms of depression and anxiety in this underserved patient population.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sixty patients (n=60) diagnosed with depressive or anxiety disorder due to another medical condition in the context of cancer or palliative care, will be recruited to the study through referrals from health care professionals at Kingston Health Sciences Centre (KHSC) including cancer centre, Providence Care Hospital (PCH), family physicians, and other health care providers or self-referrals. After consenting to take part in the study, a complete assessment will be done by one of the psychiatrists on the team to confirm the diagnosis. Inclusion criteria include 18-55 years of age at the start of the study, diagnosed with depression or anxiety secondary to a general medical condition (in the context of cancer or palliative condition) according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) by one of the psychiatrists on the team, competence to consent and participate, ability to speak and read English, and consistent and reliable access to the internet. Exclusion criteria include acute hypomanic/manic episodes, acute psychosis, severe alcohol or substance use disorder, and active suicidal or homicidal ideation or if they have received CBT in the past year or are currently receiving CBT. Participants will then be randomly assigned to two groups: e-psychotherapy group (online CBT+ mindfulness + problem solving) or treatment as usual (TAU, i.e., medication, psychiatric consultation and referrals to in-person activities/groups) arms of the study (n=30 for each group). The TAU arm acts as the control group of the study.
Upon completion of the initial assessment, if eligible for the study, participants will randomly be assigned to one of the two arms of the study. Patients in the e-CBT group will receive an 8-week online program including CBT in combination with mindfulness and problem-based therapy in addition to treatment as usual. The content of this program will be customized to reflect challenges cancer and palliative patients face through the course of their treatment and developed into interactive and engaging therapy modules. All online sessions and interactions will occur through a secure online platform (i.e. OPTT). Through the platform, the pre-designed therapy modules are assigned to the patients, accessible to them at any time throughout the week. Each module consists of approximately 30 slides, which take an average of 45-50 minutes to complete. Each weekly module highlights a different topic and includes general information, an overview of skills, and homework that is to be completed within that week. This homework can be directly submitted through the platform to the clinician who will then provide personalized feed-back to the patient. The average time spent per week by a clinician with a particular patient is about 15 minutes. The control group will receive treatment as usual in the first 8 weeks; if still significantly symptomatic (less than 50% response to treatment from baseline), they will then be offered the 8-week e-psychotherapy program.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Nazanin Alavi
- Phone Number: 73002 (613) 544 4900
- Email: nazanin.alavitabari@kingstonhsc.ca
Study Locations
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 5G3
- Recruiting
- Hôtel Dieu Hospital
-
Principal Investigator:
- Nazanin Alavi, MD FRCPC
-
Contact:
- Nazanin Alavi
- Phone Number: 6479672079
- Email: nazanin.alavitabari@kingstonhsc.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosed with depressive or anxiety disorder due to another medical condition in the context of cancer or palliative care
- competence to consent and participate
- speak and read English
- consistent and reliable access to the internet
Exclusion Criteria:
- acute hypomanic/manic episodes
- acute psychosis
- severe alcohol or substance use disorder
- active suicidal or homicidal ideation
- received CBT in the past year or are currently receiving CBT
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: e-Psychotherapy
Group will receive 8-week online program including CBT in combination with mindfulness and problem-based therapy in addition to treatment as usual.
The content will reflect challenges cancer and palliative patients face through the course of treatment and developed into interactive and engaging therapy modules.
All online sessions and interactions will occur through a secure online platform.
Pre-designed therapy modules are assigned to the patients, accessible to them at any time throughout the week.
Each module consists of approximately 30 slides, which take 45-50 minutes to complete.
Each module highlights a different topic and includes general information, an overview of skills, and homework that is to be completed within that week.
This homework can be directly submitted through the platform to the clinician who will then provide personalized feed-back to the patient.
The average time spent per week by a clinician with a particular patient is about 15 minutes.
|
e-CBT + Mindfulness + Problem Solving
|
No Intervention: Treatment as Usual
The control group will receive treatment as usual in the first 8 weeks; if still significantly symptomatic (less than 50% response to treatment from baseline), they will then be offered the 8-week e-psychotherapy program.
They will be instructed to continue with any lifestyle activities (i.e., diet, exercise, medication, etc.)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in symptoms (Functional Assessment of Cancer Therapy General - FACT-G)
Time Frame: Baseline, week 4, week 8
|
Clinically validated symptom questionnaire.
Scale of 0-4, 4 is worse.
|
Baseline, week 4, week 8
|
Change in symptoms (Patient Health Questionnaire - PHQ-9 Item)
Time Frame: Baseline, week 4, week 8
|
Clinically validated symptom questionnaire.
Scale of 0-3, 3 is worse.
|
Baseline, week 4, week 8
|
Change in symptoms (Generalized Anxiety Disorder - GAD7 Item)
Time Frame: Baseline, week 4, week 8
|
Clinically validated symptom questionnaire.
Scale of 0-3, 3 is worse.
|
Baseline, week 4, week 8
|
Change in symptoms (Quality of Life and Satisfaction Questionnaire - Q-LES-Q)
Time Frame: Baseline, week 4, week 8
|
Clinically validated symptom questionnaire.
Scale of 0-5, 5 is better.
|
Baseline, week 4, week 8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in frequency on online platform
Time Frame: Week 8
|
Logins per day
|
Week 8
|
Changes in duration on online platform
Time Frame: Week 8
|
Amount of time spent on each session
|
Week 8
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Nazanin Alavi, Queen's University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PSIY-699-20
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
Clinical Trials on e-CBT
-
Dr. Nazanin AlaviRecruiting
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicCompletedMajor Depressive DisorderCanada
-
Centro Trattamento Integrato: Disturbi Alimentari...RecruitingPersonality Disorders | Cognitive Dysfunction | Perfectionism | Emotion Regulation | Eating Disorders | Self Esteem | Social Interaction | Personality | Maladaptive Personality Trait | Dysfunctional Behavior, PsychologyItaly
-
Callum StephensonOnline PsychoTherapy ClinicCompletedObsessive-Compulsive DisorderCanada
-
Dr. Nazanin AlaviOnline PsychoTherapy ClinicRecruitingBipolar Disorder | Bipolar DepressionCanada
-
University of North Carolina, Chapel HillNational Institute of Mental Health (NIMH); University of UtahCompletedBinge-Eating DisorderUnited States
-
Federal University of São PauloUniversity of Western SydneyCompletedBulimia Nervosa | Eating Disorder | Binge Eating DisorderBrazil
-
Shalvata Mental Health CenterUniversity of Haifa; The Touro College and University SystemUnknownBinge-Eating Disorder | Bulimia Nervosa | Night-eating Syndrome
-
Dr. Nazanin AlaviCompletedDepression | Depressive Symptoms | Major Depressive DisorderCanada
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada